Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Pain Management Drugs Market by Drug Class (NSAIDs, Anesthetics, Anticonvulsants, Anti-migraine Agents, Antidepressants, Opioids, Nonnarcotic Analgesics) , by Indication (Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Back Pain, Postoperative Pain, Migraine, Fibromyalgia, Muscle Sprain/Strain, Bone Fracture, Acute Appendicitis, Others) by Pain Type (Chronic Pain, Acute Pain) : Global Opportunity Analysis and Industry Forecast, 2024-2033

A00309

Pages: 216

Charts: 70

Tables: 147

Pain Management Drugs Market Research, 2033

The global pain management drugs market size was valued at $72.6 billion in 2023, and is projected to reach $109.6 billion by 2033, growing at a CAGR of 4.2% from 2024 to 2033. The pain management drugs market is driven by aging global population prone to chronic conditions, technological advancements in drug delivery systems and formulations, and regulatory support for innovative pain therapies drives market expansion.

 Key Market Segments

  • By Drug Class
    • NSAIDs
    • Anesthetics
    • Anticonvulsants
    • Anti-migraine Agents
    • Antidepressants
    • Opioids
    • Nonnarcotic Analgesics
  • By Indication
    • Arthritic Pain
    • Neuropathic Pain
    • Cancer Pain
    • Chronic Back Pain
    • Postoperative Pain
    • Migraine
    • Fibromyalgia
    • Muscle Sprain/Strain
    • Bone Fracture
    • Acute Appendicitis
    • Others
  • By Pain Type
    • Chronic Pain
    • Acute Pain
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • UK
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • Japan
      • China
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • Saudi Arabia
      • South Africa
      • Rest of LAMEA

 
Key Market Players

  • Novartis AG
  • Purdue Pharma L.P.
  • Johnson & Johnson
  • GlaxoSmithKline Plc
  • Abbott Laboratories
  • Merck & Co. Inc.
  • Pfizer, Inc.
  • Viatris Inc.
  • Endo Health Solutions, Inc.
  • Eli Lilly & Company

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Drug Class

    • 4.2. NSAIDs

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Anesthetics

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Anticonvulsants

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Anti-migraine Agents

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Antidepressants

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

    • 4.7. Opioids

      • 4.7.1. Key Market Trends, Growth Factors and Opportunities

      • 4.7.2. Market Size and Forecast, By Region

      • 4.7.3. Market Share Analysis, By Country

    • 4.8. Nonnarcotic Analgesics

      • 4.8.1. Key Market Trends, Growth Factors and Opportunities

      • 4.8.2. Market Size and Forecast, By Region

      • 4.8.3. Market Share Analysis, By Country

  • CHAPTER 5: PAIN MANAGEMENT DRUGS MARKET, BY INDICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Indication

    • 5.2. Arthritic Pain

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Neuropathic Pain

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Cancer Pain

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Chronic Back Pain

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Postoperative Pain

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

    • 5.7. Migraine

      • 5.7.1. Key Market Trends, Growth Factors and Opportunities

      • 5.7.2. Market Size and Forecast, By Region

      • 5.7.3. Market Share Analysis, By Country

    • 5.8. Fibromyalgia

      • 5.8.1. Key Market Trends, Growth Factors and Opportunities

      • 5.8.2. Market Size and Forecast, By Region

      • 5.8.3. Market Share Analysis, By Country

    • 5.9. Muscle Sprain/Strain

      • 5.9.1. Key Market Trends, Growth Factors and Opportunities

      • 5.9.2. Market Size and Forecast, By Region

      • 5.9.3. Market Share Analysis, By Country

    • 5.10. Bone Fracture

      • 5.10.1. Key Market Trends, Growth Factors and Opportunities

      • 5.10.2. Market Size and Forecast, By Region

      • 5.10.3. Market Share Analysis, By Country

    • 5.11. Acute Appendicitis

      • 5.11.1. Key Market Trends, Growth Factors and Opportunities

      • 5.11.2. Market Size and Forecast, By Region

      • 5.11.3. Market Share Analysis, By Country

    • 5.12. Others

      • 5.12.1. Key Market Trends, Growth Factors and Opportunities

      • 5.12.2. Market Size and Forecast, By Region

      • 5.12.3. Market Share Analysis, By Country

  • CHAPTER 6: PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Pain Type

    • 6.2. Chronic Pain

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Acute Pain

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

  • CHAPTER 7: PAIN MANAGEMENT DRUGS MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Drug Class

      • 7.2.3. Market Size and Forecast, By Indication

      • 7.2.4. Market Size and Forecast, By Pain Type

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Pain Management Drugs Market

        • 7.2.6.1. Market Size and Forecast, By Drug Class
        • 7.2.6.2. Market Size and Forecast, By Indication
        • 7.2.6.3. Market Size and Forecast, By Pain Type

      • 7.2.7. Canada Pain Management Drugs Market

        • 7.2.7.1. Market Size and Forecast, By Drug Class
        • 7.2.7.2. Market Size and Forecast, By Indication
        • 7.2.7.3. Market Size and Forecast, By Pain Type

      • 7.2.8. Mexico Pain Management Drugs Market

        • 7.2.8.1. Market Size and Forecast, By Drug Class
        • 7.2.8.2. Market Size and Forecast, By Indication
        • 7.2.8.3. Market Size and Forecast, By Pain Type

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Drug Class

      • 7.3.3. Market Size and Forecast, By Indication

      • 7.3.4. Market Size and Forecast, By Pain Type

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Pain Management Drugs Market

        • 7.3.6.1. Market Size and Forecast, By Drug Class
        • 7.3.6.2. Market Size and Forecast, By Indication
        • 7.3.6.3. Market Size and Forecast, By Pain Type

      • 7.3.7. Germany Pain Management Drugs Market

        • 7.3.7.1. Market Size and Forecast, By Drug Class
        • 7.3.7.2. Market Size and Forecast, By Indication
        • 7.3.7.3. Market Size and Forecast, By Pain Type

      • 7.3.8. Italy Pain Management Drugs Market

        • 7.3.8.1. Market Size and Forecast, By Drug Class
        • 7.3.8.2. Market Size and Forecast, By Indication
        • 7.3.8.3. Market Size and Forecast, By Pain Type

      • 7.3.9. Spain Pain Management Drugs Market

        • 7.3.9.1. Market Size and Forecast, By Drug Class
        • 7.3.9.2. Market Size and Forecast, By Indication
        • 7.3.9.3. Market Size and Forecast, By Pain Type

      • 7.3.10. UK Pain Management Drugs Market

        • 7.3.10.1. Market Size and Forecast, By Drug Class
        • 7.3.10.2. Market Size and Forecast, By Indication
        • 7.3.10.3. Market Size and Forecast, By Pain Type

      • 7.3.11. Russia Pain Management Drugs Market

        • 7.3.11.1. Market Size and Forecast, By Drug Class
        • 7.3.11.2. Market Size and Forecast, By Indication
        • 7.3.11.3. Market Size and Forecast, By Pain Type

      • 7.3.12. Rest Of Europe Pain Management Drugs Market

        • 7.3.12.1. Market Size and Forecast, By Drug Class
        • 7.3.12.2. Market Size and Forecast, By Indication
        • 7.3.12.3. Market Size and Forecast, By Pain Type

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Drug Class

      • 7.4.3. Market Size and Forecast, By Indication

      • 7.4.4. Market Size and Forecast, By Pain Type

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Pain Management Drugs Market

        • 7.4.6.1. Market Size and Forecast, By Drug Class
        • 7.4.6.2. Market Size and Forecast, By Indication
        • 7.4.6.3. Market Size and Forecast, By Pain Type

      • 7.4.7. Japan Pain Management Drugs Market

        • 7.4.7.1. Market Size and Forecast, By Drug Class
        • 7.4.7.2. Market Size and Forecast, By Indication
        • 7.4.7.3. Market Size and Forecast, By Pain Type

      • 7.4.8. India Pain Management Drugs Market

        • 7.4.8.1. Market Size and Forecast, By Drug Class
        • 7.4.8.2. Market Size and Forecast, By Indication
        • 7.4.8.3. Market Size and Forecast, By Pain Type

      • 7.4.9. South Korea Pain Management Drugs Market

        • 7.4.9.1. Market Size and Forecast, By Drug Class
        • 7.4.9.2. Market Size and Forecast, By Indication
        • 7.4.9.3. Market Size and Forecast, By Pain Type

      • 7.4.10. Australia Pain Management Drugs Market

        • 7.4.10.1. Market Size and Forecast, By Drug Class
        • 7.4.10.2. Market Size and Forecast, By Indication
        • 7.4.10.3. Market Size and Forecast, By Pain Type

      • 7.4.11. Thailand Pain Management Drugs Market

        • 7.4.11.1. Market Size and Forecast, By Drug Class
        • 7.4.11.2. Market Size and Forecast, By Indication
        • 7.4.11.3. Market Size and Forecast, By Pain Type

      • 7.4.12. Malaysia Pain Management Drugs Market

        • 7.4.12.1. Market Size and Forecast, By Drug Class
        • 7.4.12.2. Market Size and Forecast, By Indication
        • 7.4.12.3. Market Size and Forecast, By Pain Type

      • 7.4.13. Indonesia Pain Management Drugs Market

        • 7.4.13.1. Market Size and Forecast, By Drug Class
        • 7.4.13.2. Market Size and Forecast, By Indication
        • 7.4.13.3. Market Size and Forecast, By Pain Type

      • 7.4.14. Rest of Asia Pacific Pain Management Drugs Market

        • 7.4.14.1. Market Size and Forecast, By Drug Class
        • 7.4.14.2. Market Size and Forecast, By Indication
        • 7.4.14.3. Market Size and Forecast, By Pain Type

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Drug Class

      • 7.5.3. Market Size and Forecast, By Indication

      • 7.5.4. Market Size and Forecast, By Pain Type

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Pain Management Drugs Market

        • 7.5.6.1. Market Size and Forecast, By Drug Class
        • 7.5.6.2. Market Size and Forecast, By Indication
        • 7.5.6.3. Market Size and Forecast, By Pain Type

      • 7.5.7. South Africa Pain Management Drugs Market

        • 7.5.7.1. Market Size and Forecast, By Drug Class
        • 7.5.7.2. Market Size and Forecast, By Indication
        • 7.5.7.3. Market Size and Forecast, By Pain Type

      • 7.5.8. Saudi Arabia Pain Management Drugs Market

        • 7.5.8.1. Market Size and Forecast, By Drug Class
        • 7.5.8.2. Market Size and Forecast, By Indication
        • 7.5.8.3. Market Size and Forecast, By Pain Type

      • 7.5.9. UAE Pain Management Drugs Market

        • 7.5.9.1. Market Size and Forecast, By Drug Class
        • 7.5.9.2. Market Size and Forecast, By Indication
        • 7.5.9.3. Market Size and Forecast, By Pain Type

      • 7.5.10. Argentina Pain Management Drugs Market

        • 7.5.10.1. Market Size and Forecast, By Drug Class
        • 7.5.10.2. Market Size and Forecast, By Indication
        • 7.5.10.3. Market Size and Forecast, By Pain Type

      • 7.5.11. Rest of LAMEA Pain Management Drugs Market

        • 7.5.11.1. Market Size and Forecast, By Drug Class
        • 7.5.11.2. Market Size and Forecast, By Indication
        • 7.5.11.3. Market Size and Forecast, By Pain Type

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning, 2024

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Novartis AG

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Eli Lilly And Company

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Abbott Laboratories

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Endo Health Solutions, Inc.

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Purdue Pharma L.P.

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Pfizer, Inc.

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Viatris Inc.

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Merck And Co. Inc.

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Johnson And Johnson

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. GlaxoSmithKline Plc

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL PAIN MANAGEMENT DRUGS MARKET FOR NSAIDS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL PAIN MANAGEMENT DRUGS MARKET FOR ANESTHETICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL PAIN MANAGEMENT DRUGS MARKET FOR ANTICONVULSANTS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL PAIN MANAGEMENT DRUGS MARKET FOR ANTI-MIGRAINE AGENTS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL PAIN MANAGEMENT DRUGS MARKET FOR ANTIDEPRESSANTS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL PAIN MANAGEMENT DRUGS MARKET FOR OPIOIDS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL PAIN MANAGEMENT DRUGS MARKET FOR NONNARCOTIC ANALGESICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL PAIN MANAGEMENT DRUGS MARKET FOR ARTHRITIC PAIN, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL PAIN MANAGEMENT DRUGS MARKET FOR NEUROPATHIC PAIN, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL PAIN MANAGEMENT DRUGS MARKET FOR CANCER PAIN, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL PAIN MANAGEMENT DRUGS MARKET FOR CHRONIC BACK PAIN, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. GLOBAL PAIN MANAGEMENT DRUGS MARKET FOR POSTOPERATIVE PAIN, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. GLOBAL PAIN MANAGEMENT DRUGS MARKET FOR MIGRAINE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 16. GLOBAL PAIN MANAGEMENT DRUGS MARKET FOR FIBROMYALGIA, BY REGION, 2025-2033 ($MILLION)
  • TABLE 17. GLOBAL PAIN MANAGEMENT DRUGS MARKET FOR MUSCLE SPRAIN/STRAIN, BY REGION, 2025-2033 ($MILLION)
  • TABLE 18. GLOBAL PAIN MANAGEMENT DRUGS MARKET FOR BONE FRACTURE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 19. GLOBAL PAIN MANAGEMENT DRUGS MARKET FOR ACUTE APPENDICITIS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 20. GLOBAL PAIN MANAGEMENT DRUGS MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 21. GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2025-2033 ($MILLION)
  • TABLE 22. GLOBAL PAIN MANAGEMENT DRUGS MARKET FOR CHRONIC PAIN, BY REGION, 2025-2033 ($MILLION)
  • TABLE 23. GLOBAL PAIN MANAGEMENT DRUGS MARKET FOR ACUTE PAIN, BY REGION, 2025-2033 ($MILLION)
  • TABLE 24. GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 25. NORTH AMERICA PAIN MANAGEMENT DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 26. NORTH AMERICA PAIN MANAGEMENT DRUGS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 27. NORTH AMERICA PAIN MANAGEMENT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 28. NORTH AMERICA PAIN MANAGEMENT DRUGS, BY PAIN TYPE, 2025-2033 ($MILLION)
  • TABLE 29. U.S. PAIN MANAGEMENT DRUGS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 30. U.S. PAIN MANAGEMENT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 31. U.S. PAIN MANAGEMENT DRUGS, BY PAIN TYPE, 2025-2033 ($MILLION)
  • TABLE 32. CANADA PAIN MANAGEMENT DRUGS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 33. CANADA PAIN MANAGEMENT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 34. CANADA PAIN MANAGEMENT DRUGS, BY PAIN TYPE, 2025-2033 ($MILLION)
  • TABLE 35. MEXICO PAIN MANAGEMENT DRUGS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 36. MEXICO PAIN MANAGEMENT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 37. MEXICO PAIN MANAGEMENT DRUGS, BY PAIN TYPE, 2025-2033 ($MILLION)
  • TABLE 38. EUROPE PAIN MANAGEMENT DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 39. EUROPE PAIN MANAGEMENT DRUGS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 40. EUROPE PAIN MANAGEMENT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 41. EUROPE PAIN MANAGEMENT DRUGS, BY PAIN TYPE, 2025-2033 ($MILLION)
  • TABLE 42. FRANCE PAIN MANAGEMENT DRUGS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 43. FRANCE PAIN MANAGEMENT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 44. FRANCE PAIN MANAGEMENT DRUGS, BY PAIN TYPE, 2025-2033 ($MILLION)
  • TABLE 45. GERMANY PAIN MANAGEMENT DRUGS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 46. GERMANY PAIN MANAGEMENT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 47. GERMANY PAIN MANAGEMENT DRUGS, BY PAIN TYPE, 2025-2033 ($MILLION)
  • TABLE 48. ITALY PAIN MANAGEMENT DRUGS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 49. ITALY PAIN MANAGEMENT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 50. ITALY PAIN MANAGEMENT DRUGS, BY PAIN TYPE, 2025-2033 ($MILLION)
  • TABLE 51. SPAIN PAIN MANAGEMENT DRUGS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 52. SPAIN PAIN MANAGEMENT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 53. SPAIN PAIN MANAGEMENT DRUGS, BY PAIN TYPE, 2025-2033 ($MILLION)
  • TABLE 54. UK PAIN MANAGEMENT DRUGS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 55. UK PAIN MANAGEMENT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 56. UK PAIN MANAGEMENT DRUGS, BY PAIN TYPE, 2025-2033 ($MILLION)
  • TABLE 57. RUSSIA PAIN MANAGEMENT DRUGS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 58. RUSSIA PAIN MANAGEMENT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 59. RUSSIA PAIN MANAGEMENT DRUGS, BY PAIN TYPE, 2025-2033 ($MILLION)
  • TABLE 60. REST OF EUROPE PAIN MANAGEMENT DRUGS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 61. REST OF EUROPE PAIN MANAGEMENT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 62. REST OF EUROPE PAIN MANAGEMENT DRUGS, BY PAIN TYPE, 2025-2033 ($MILLION)
  • TABLE 63. ASIA-PACIFIC PAIN MANAGEMENT DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 64. ASIA-PACIFIC PAIN MANAGEMENT DRUGS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 65. ASIA-PACIFIC PAIN MANAGEMENT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 66. ASIA-PACIFIC PAIN MANAGEMENT DRUGS, BY PAIN TYPE, 2025-2033 ($MILLION)
  • TABLE 67. CHINA PAIN MANAGEMENT DRUGS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 68. CHINA PAIN MANAGEMENT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 69. CHINA PAIN MANAGEMENT DRUGS, BY PAIN TYPE, 2025-2033 ($MILLION)
  • TABLE 70. JAPAN PAIN MANAGEMENT DRUGS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 71. JAPAN PAIN MANAGEMENT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 72. JAPAN PAIN MANAGEMENT DRUGS, BY PAIN TYPE, 2025-2033 ($MILLION)
  • TABLE 73. INDIA PAIN MANAGEMENT DRUGS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 74. INDIA PAIN MANAGEMENT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 75. INDIA PAIN MANAGEMENT DRUGS, BY PAIN TYPE, 2025-2033 ($MILLION)
  • TABLE 76. SOUTH KOREA PAIN MANAGEMENT DRUGS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 77. SOUTH KOREA PAIN MANAGEMENT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 78. SOUTH KOREA PAIN MANAGEMENT DRUGS, BY PAIN TYPE, 2025-2033 ($MILLION)
  • TABLE 79. AUSTRALIA PAIN MANAGEMENT DRUGS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 80. AUSTRALIA PAIN MANAGEMENT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 81. AUSTRALIA PAIN MANAGEMENT DRUGS, BY PAIN TYPE, 2025-2033 ($MILLION)
  • TABLE 82. THAILAND PAIN MANAGEMENT DRUGS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 83. THAILAND PAIN MANAGEMENT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 84. THAILAND PAIN MANAGEMENT DRUGS, BY PAIN TYPE, 2025-2033 ($MILLION)
  • TABLE 85. MALAYSIA PAIN MANAGEMENT DRUGS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 86. MALAYSIA PAIN MANAGEMENT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 87. MALAYSIA PAIN MANAGEMENT DRUGS, BY PAIN TYPE, 2025-2033 ($MILLION)
  • TABLE 88. INDONESIA PAIN MANAGEMENT DRUGS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 89. INDONESIA PAIN MANAGEMENT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 90. INDONESIA PAIN MANAGEMENT DRUGS, BY PAIN TYPE, 2025-2033 ($MILLION)
  • TABLE 91. REST OF ASIA PACIFIC PAIN MANAGEMENT DRUGS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 92. REST OF ASIA PACIFIC PAIN MANAGEMENT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 93. REST OF ASIA PACIFIC PAIN MANAGEMENT DRUGS, BY PAIN TYPE, 2025-2033 ($MILLION)
  • TABLE 94. LAMEA PAIN MANAGEMENT DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 95. LAMEA PAIN MANAGEMENT DRUGS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 96. LAMEA PAIN MANAGEMENT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 97. LAMEA PAIN MANAGEMENT DRUGS, BY PAIN TYPE, 2025-2033 ($MILLION)
  • TABLE 98. BRAZIL PAIN MANAGEMENT DRUGS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 99. BRAZIL PAIN MANAGEMENT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 100. BRAZIL PAIN MANAGEMENT DRUGS, BY PAIN TYPE, 2025-2033 ($MILLION)
  • TABLE 101. SOUTH AFRICA PAIN MANAGEMENT DRUGS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 102. SOUTH AFRICA PAIN MANAGEMENT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 103. SOUTH AFRICA PAIN MANAGEMENT DRUGS, BY PAIN TYPE, 2025-2033 ($MILLION)
  • TABLE 104. SAUDI ARABIA PAIN MANAGEMENT DRUGS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 105. SAUDI ARABIA PAIN MANAGEMENT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 106. SAUDI ARABIA PAIN MANAGEMENT DRUGS, BY PAIN TYPE, 2025-2033 ($MILLION)
  • TABLE 107. UAE PAIN MANAGEMENT DRUGS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 108. UAE PAIN MANAGEMENT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 109. UAE PAIN MANAGEMENT DRUGS, BY PAIN TYPE, 2025-2033 ($MILLION)
  • TABLE 110. ARGENTINA PAIN MANAGEMENT DRUGS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 111. ARGENTINA PAIN MANAGEMENT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 112. ARGENTINA PAIN MANAGEMENT DRUGS, BY PAIN TYPE, 2025-2033 ($MILLION)
  • TABLE 113. REST OF LAMEA PAIN MANAGEMENT DRUGS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 114. REST OF LAMEA PAIN MANAGEMENT DRUGS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 115. REST OF LAMEA PAIN MANAGEMENT DRUGS, BY PAIN TYPE, 2025-2033 ($MILLION)
  • TABLE 116. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 117. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 118. NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 119. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 120. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 121. ELI LILLY AND COMPANY: KEY EXECUTIVES
  • TABLE 122. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 123. ELI LILLY AND COMPANY: OPERATING SEGMENTS
  • TABLE 124. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 125. ELI LILLY AND COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 126. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 127. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 128. ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 129. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 130. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 131. ENDO HEALTH SOLUTIONS, INC.: KEY EXECUTIVES
  • TABLE 132. ENDO HEALTH SOLUTIONS, INC.: COMPANY SNAPSHOT
  • TABLE 133. ENDO HEALTH SOLUTIONS, INC.: OPERATING SEGMENTS
  • TABLE 134. ENDO HEALTH SOLUTIONS, INC.: PRODUCT PORTFOLIO
  • TABLE 135. ENDO HEALTH SOLUTIONS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 136. PURDUE PHARMA L.P.: KEY EXECUTIVES
  • TABLE 137. PURDUE PHARMA L.P.: COMPANY SNAPSHOT
  • TABLE 138. PURDUE PHARMA L.P.: OPERATING SEGMENTS
  • TABLE 139. PURDUE PHARMA L.P.: PRODUCT PORTFOLIO
  • TABLE 140. PURDUE PHARMA L.P.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 141. PFIZER, INC.: KEY EXECUTIVES
  • TABLE 142. PFIZER, INC.: COMPANY SNAPSHOT
  • TABLE 143. PFIZER, INC.: OPERATING SEGMENTS
  • TABLE 144. PFIZER, INC.: PRODUCT PORTFOLIO
  • TABLE 145. PFIZER, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 146. VIATRIS INC.: KEY EXECUTIVES
  • TABLE 147. VIATRIS INC.: COMPANY SNAPSHOT
  • TABLE 148. VIATRIS INC.: OPERATING SEGMENTS
  • TABLE 149. VIATRIS INC.: PRODUCT PORTFOLIO
  • TABLE 150. VIATRIS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 151. MERCK AND CO. INC.: KEY EXECUTIVES
  • TABLE 152. MERCK AND CO. INC.: COMPANY SNAPSHOT
  • TABLE 153. MERCK AND CO. INC.: OPERATING SEGMENTS
  • TABLE 154. MERCK AND CO. INC.: PRODUCT PORTFOLIO
  • TABLE 155. MERCK AND CO. INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 156. JOHNSON AND JOHNSON: KEY EXECUTIVES
  • TABLE 157. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
  • TABLE 158. JOHNSON AND JOHNSON: OPERATING SEGMENTS
  • TABLE 159. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
  • TABLE 160. JOHNSON AND JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 161. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
  • TABLE 162. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 163. GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
  • TABLE 164. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 165. GLAXOSMITHKLINE PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL PAIN MANAGEMENT DRUGS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL PAIN MANAGEMENT DRUGS MARKET
  • FIGURE 3. SEGMENTATION PAIN MANAGEMENT DRUGS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN PAIN MANAGEMENT DRUGS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALPAIN MANAGEMENT DRUGS MARKET
  • FIGURE 11. PAIN MANAGEMENT DRUGS MARKET SEGMENTATION, BY BY DRUG CLASS
  • FIGURE 12. PAIN MANAGEMENT DRUGS MARKET FOR NSAIDS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. PAIN MANAGEMENT DRUGS MARKET FOR ANESTHETICS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. PAIN MANAGEMENT DRUGS MARKET FOR ANTICONVULSANTS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. PAIN MANAGEMENT DRUGS MARKET FOR ANTI-MIGRAINE AGENTS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. PAIN MANAGEMENT DRUGS MARKET FOR ANTIDEPRESSANTS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. PAIN MANAGEMENT DRUGS MARKET FOR OPIOIDS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. PAIN MANAGEMENT DRUGS MARKET FOR NONNARCOTIC ANALGESICS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. PAIN MANAGEMENT DRUGS MARKET SEGMENTATION, BY BY INDICATION
  • FIGURE 20. PAIN MANAGEMENT DRUGS MARKET FOR ARTHRITIC PAIN, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. PAIN MANAGEMENT DRUGS MARKET FOR NEUROPATHIC PAIN, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 22. PAIN MANAGEMENT DRUGS MARKET FOR CANCER PAIN, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 23. PAIN MANAGEMENT DRUGS MARKET FOR CHRONIC BACK PAIN, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 24. PAIN MANAGEMENT DRUGS MARKET FOR POSTOPERATIVE PAIN, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 25. PAIN MANAGEMENT DRUGS MARKET FOR MIGRAINE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 26. PAIN MANAGEMENT DRUGS MARKET FOR FIBROMYALGIA, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 27. PAIN MANAGEMENT DRUGS MARKET FOR MUSCLE SPRAIN/STRAIN, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 28. PAIN MANAGEMENT DRUGS MARKET FOR BONE FRACTURE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 29. PAIN MANAGEMENT DRUGS MARKET FOR ACUTE APPENDICITIS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 30. PAIN MANAGEMENT DRUGS MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 31. PAIN MANAGEMENT DRUGS MARKET SEGMENTATION, BY BY PAIN TYPE
  • FIGURE 32. PAIN MANAGEMENT DRUGS MARKET FOR CHRONIC PAIN, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 33. PAIN MANAGEMENT DRUGS MARKET FOR ACUTE PAIN, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 34. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 35. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 36. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 37. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 38. COMPETITIVE DASHBOARD
  • FIGURE 39. COMPETITIVE HEATMAP: PAIN MANAGEMENT DRUGS MARKET
  • FIGURE 40. TOP PLAYER POSITIONING, 2024
  • FIGURE 41. NOVARTIS AG: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 42. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 43. NOVARTIS AG: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 44. ELI LILLY AND COMPANY: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 45. ELI LILLY AND COMPANY: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 46. ELI LILLY AND COMPANY: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 47. ABBOTT LABORATORIES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 48. ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 49. ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 50. ENDO HEALTH SOLUTIONS, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 51. ENDO HEALTH SOLUTIONS, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 52. ENDO HEALTH SOLUTIONS, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 53. PURDUE PHARMA L.P.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 54. PURDUE PHARMA L.P.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 55. PURDUE PHARMA L.P.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 56. PFIZER, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 57. PFIZER, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 58. PFIZER, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 59. VIATRIS INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 60. VIATRIS INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 61. VIATRIS INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 62. MERCK AND CO. INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 63. MERCK AND CO. INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 64. MERCK AND CO. INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 65. JOHNSON AND JOHNSON: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 66. JOHNSON AND JOHNSON: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 67. JOHNSON AND JOHNSON: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 68. GLAXOSMITHKLINE PLC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 69. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 70. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Pain Management Drugs Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved